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Abstract
Purpose Previous studies have shown that > 50% of colorectal cancer (CRC) patients treated with adjuvant chemotherapy gain
weight after diagnosis. This may affect long-term health. Therefore, prevention of weight gain has been incorporated in onco-
logical guidelines for CRCwith a focus on patients that undergo adjuvant chemotherapy treatment. It is, however, unknown how
changes in weight after diagnosis relate to weight before diagnosis and whether weight changes from pre-to-post diagnosis are
restricted to chemotherapy treatment. We therefore examined pre-to-post diagnosis weight trajectories and compared them
between those treated with and without adjuvant chemotherapy.
Methods We included 1184 patients diagnosed with stages I–III CRC between 2010 and 2015 from an ongoing observational
prospective study. At diagnosis, patients reported current weight and usual weight 2 years before diagnosis. In the 2 years
following diagnosis, weight was self-reported repeatedly. We used linear mixed models to analyse weight trajectories.
Results Mean pre-to-post diagnosis weight change was −0.8 (95%CI −1.1, −0.4) kg. Post-diagnosis weight gain was + 3.5 (95%
CI 2.7, 4.3) kg in patients who had lost ≥ 5% weight before diagnosis, while on average clinically relevant weight gain after
diagnosis was absent in the groups without pre-diagnosis weight loss. Pre-to-post diagnosis weight change was similar in patients
treated with (−0.1 kg (95%CI −0.8, 0.6)) and without adjuvant chemotherapy (−0.9 kg (95%CI −1.4, −0.5)).
Conclusions Overall, hardly any pre-to-post diagnosis weight change was observed among CRC patients, because post-diagnosis
weight gain was mainly observed in patients who lost weight before diagnosis. This was observed independent of treatment with
adjuvant chemotherapy.
Keywords Colorectal cancer .Weight change .Weight gain . Chemotherapy
Introduction
Survival of colorectal cancer (CRC) has markedly improved
over recent decades, which underlines the importance to study
factors that can affect long-term health and quality of life of
CRC survivors. One of the factors that may affect health and
quality of life is body weight. Weight loss, either before diag-
nosis or during cancer treatment, is an important negative
prognostic marker [1–4]. Therefore, in the hospital nutritional
advice to cancer patients is mainly focused on prevention and/
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or treatment of unintentional weight loss. However, over-
weight and obesity are also affecting long-term health and
quality of life among patients with non-metastatic disease.
Therefore, prevention of weight gain after CRC diagnosis
has recently been incorporated in the Dutch oncological nu-
tritional therapy guidelines [5].
Many CRC patients are overweight or obese at diagnosis,
as excess body weight is a risk factor for CRC [6].
Overweight/obese CRC survivors have an elevated risk of
co-morbid disease, such as cardiovascular disease and diabe-
tes, both at diagnosis and in the years following a diagnosis
[7–9]. Weight gain after diagnosis might exacerbate existing
co-morbid disease progression and further increase the risk of
developing such diseases. Several studies reported that weight
gain after diagnosis is common among CRC patients [1–3, 10,
11]. All these studies showed that weight gain after diagnosis
was more common than weight loss after diagnosis [1–3, 10,
11]. The proportion of weight gain after diagnosis typically
ranged from 25% to over 50% of patients [1–3, 10, 11]. In
these studies, weight gain was defined as either a weight gain
of ≥ 5 kg [1, 10] or ≥ 5% [2, 3, 11].
Although body weight may increase after CRC diagnosis,
studies so far did not assess how body weight changed relative
to usual body weight before diagnosis. Weight loss before
CRC diagnosis is common [4, 12] as unintended weight loss
could be one of the reasons for patients to see a physician,
leading to the diagnosis of CRC. Thus, it is possible that
patients catch up for this pre-diagnostic weight loss in the
period during and after treatment. It is currently unknown if
post-diagnosis weight change is different for patients with pre-
diagnosis weight change compared to patients who were
weight stable before diagnosis. Post-diagnosis weight gain
might be more problematic in terms of long-term health if it
results in overall weight gain compared to usual weight than
when it reflects catching up for pre-diagnostic weight loss.
Weight gain is a common side-effect of chemotherapy
in breast cancer patients [13], but weight gain is also
common among non-metastatic CRC patients during and
after chemotherapy. Two studies that both included >
500 colon cancer patients with stage III disease treated
with adjuvant chemotherapy reported that the majority
(51–65%) of patients experienced weight gain [3, 10].
Weight gain is observed both during and after adjuvant
chemotherapy [11]. Therefore, prevention of weight gain
in oncological guidelines has a focus on patients treated
with adjuvant chemotherapy [5]. However, there is only
indirect evidence that weight gain after diagnosis is
more prevalent among patients treated with adjuvant
chemotherapy than among patients treated without adju-
vant chemotherapy. Studies that included non-metastatic
CRC patients irrespective of chemotherapy treatment re-
ported lower proportions (28%) of weight gain [1, 2]
than studies among CRC patients treated with adjuvant
chemotherapy (51–65%) [3, 10]. There are no studies
that directly compared weight changes between patients
treated with or without adjuvant chemotherapy.
Weight trajectories should ideally include data on weight at
multiple time points, both before and after diagnosis, to fully
capture weight changes among CRC patients. This informa-
tion is currently lacking and therefore it remains unclear
whether post-diagnosis weight eventually surpasses usual
pre-diagnosis weight. Our aim was to examine pre-to-post
diagnosis weight trajectories in CRC patients with non-
metastatic disease and to compare these weight trajectories
among patients treated with and without adjuvant
chemotherapy.
Methods
Study population
We used data of the COLON study, an ongoing pro-
spective multicentre cohort study among CRC patients
in the Netherlands [14]. Eligible participants with newly
diagnosed colon or rectal cancer were invited by hospi-
tal staff to participate in the study during a routine
clinical visit before scheduled surgery. Data were col-
lected shortly after diagnosis, before treatment started,
and at two or three time points in the first 2 years after
diagnosis (see BAssessment of body weight^). Follow-up
data were available until January 2018. All study par-
ticipants provided written informed consent and the
study was approved by the local review board.
This study was performed among all participants diag-
nosed with stage I–III CRC between 2010 and 2015 who
had a surgical resection (n = 1225). We excluded 70 partici-
pants who had information on weight available for < 2 time
points. Thus, data of 1152 participants remained for analyses.
Of these participants, 16 (1%) had missing self-reported
weight before diagnosis and 217 (19%) did not complete
2 years of follow-up. We chose to exclude patients with stage
IV disease a priori, because survival for these patients is gen-
erally poor and weight loss and cachexia are common at the
end of life.
Assessment of body weight
At diagnosis, participants completed a survey with questions
on body weight 2 years prior to diagnosis, and current weight.
Participants repetitively answered surveys about their current
body weight at 6 months, 1 year (only for the subsample
treated with adjuvant chemotherapy), and 2 years after
diagnosis.
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Assessment of covariates
We obtained information on clinical factors, including disease
stage, tumour site, receipt of neo-adjuvant treatment, type of
surgery, stoma placement after surgery, complications within
30 days after surgery, receipt of adjuvant chemotherapy, type
of chemotherapy, and presence of comorbidities from the
Dutch ColoRectal Audit [15]. At diagnosis, all participants
completed a questionnaire on demographic and lifestyle infor-
mation, including education, smoking behaviour, and height.
Body mass index (BMI) at diagnosis was computed in kg/m2.
Statistical analyses
We calculated pre-diagnosis, post-diagnosis, and pre-to-post
diagnosis weight changes as weight at the end of the period
minus weight at the start of the period, so negative differences
indicate weight loss and positive differences indicate weight
gain. Pre-diagnostic weight changes were grouped in three
pre-defined categories: weight loss ≥ 5%, weight stable −5
to +5%, and weight gain ≥ 5%. Characteristics of the study
population were compared across pre-diagnosis weight
change groups and across adjuvant chemotherapy treatment.
Differences in categorical variables were assessed by using a
chi-squared test, and differences in means of continuous var-
iables were tested by using analysis of variance or a t-test.
We fitted linear mixed models to examine weight trajecto-
ries over 4 years (2 years pre-diagnosis to 2 years post-diag-
nosis). Linear mixed models take into account both the indi-
vidual trajectories of change (random effects) and population
averages (fixed effects) by using all available measurements
and including participants with incomplete data [16]. Time
was scaled in years (continuous) with the date of study enrol-
ment (shortly after diagnosis) defined as time is zero. Time for
each post-diagnosis weight was calculated as date of self-
reported weight collection minus the date of study enrolment.
Time for pre-diagnosis weight was set at −2 years for all
subjects.
The final model included a random intercept, a random
slope for time, and a random curvature for time (i.e. taking
into account each participant’s weight at diagnosis and the
linear and quadratic slope). Using a step-up model building
strategy, the random curvature model had much better fit than
a random intercept model and a random slope model.
As fixed factors, we included baseline demographic deter-
minants (sex, age, height, education, and smoking) and clini-
cal factors (stage, tumour site, neo-adjuvant treatment, stoma,
type of surgery, complications after surgery, and comorbidi-
ties). Age and height were centred to aid the interpretability of
intercepts. The clinical factors neo-adjuvant treatment, stoma,
and surgical complications were coded as not present before
and at diagnosis. All fixed effects were included in the model
as an interaction term with time. Only significant covariates
and/or interactions were retained. Including additional inter-
actions with time*time for the remaining covariates did not
improve the model. The final model used in all analyses in-
cluded the following fixed factors: time, sex, age, height, ed-
ucation, smoking, complications, stoma, type of surgery, co-
mo r b i d i t i e s , t ime* t ime , e d u c a t i o n * t ime , a n d
complications*time. The coefficient for time represents aver-
age annual linear change and the coefficient for time*time
captures additional quadratic (curvilinear) change in weight
in kilogrammes.
Additionally, we performed several stratified weight trajec-
tory analyses. First, we stratified by pre-diagnosis weight
change category (≥ 5% loss, stable, ≥ 5% gain) to further ex-
plore if weight gain after diagnosis differed by pre-diagnosis
weight change. Second, we stratified by receipt of chemother-
apy to compare weight trajectories among those treated with
and without adjuvant chemotherapy. Third, as an exploratory
analysis, we stratified by BMI at diagnosis to compare weight
trajectories among survivors with a healthy BMI (18.5–25 kg/
m2) and those with overweight or obesity (BMI ≥ 25 kg/m2).
Weight trajectories were depicted based on predicted values
by using the average study population, except for type of
surgery in which laparoscopic surgery served as reference
category. Two sensitivity analyses were performed to reduce
heterogeneity between patients in the analyses stratified by
chemotherapy. First by excluding patients with other adjuvant
chemotherapy regimens than capecitabine combined with
oxaliplatin and second by excluding patients with rectal tu-
mours from the analyses. In the Netherlands, rectal tumours
are generally not treated with adjuvant chemotherapy, which
is in line with the Dutch oncological guidelines.
In all analyses, a p value < 0.05 was considered statistically
significant. Statistical analyses were performed in SAS 9.4
(SAS Institute, Cary, NC).
Results
Characteristics of the study population according to pre-
diagnosis weight change and adjuvant chemotherapy are
shown in Table 1. Participants with ≥ 5% weight gain before
diagnosis were on average slightly younger, more commonly
female, obese at diagnosis (BMI ≥ 30 kg/m2), and presenting
with one or more comorbidities compared to those with either
stable weight or ≥ 5% weight loss before diagnosis.
Participants with ≥ 5% weight loss before diagnosis had more
often a tumour located in the colon compared to those with
stable weight or weight gain. Patients treated with adjuvant
chemotherapy were slightly younger and had unfavourable
clinical characteristics compared to patients not treated with
chemotherapy; other characteristics, such as BMI, were simi-
lar between the two groups.
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Table 1 Clinical and personal characteristics of 1152 non-metastatic colorectal cancer patients according to pre-diagnosis weight change and adjuvant
chemotherapy1
Weight change in the 2 years before diagnosis Adjuvant chemotherapy
Overall2 Loss
(≥ 5%)
Stable (−5% to 5%) Gain
(≥ 5%)
p value weight
change group
No Yes p value chemo
therapy
N (%) 1152
(100%)
279 (25%) 788 (69%) 69 (6%) 844 (75%) 282 (25%)
Sex < 0.001 0.21
Men 737 (64%) 179 (64%) 527 (67%) 19 (28%) 547 (65%) 171 (61%)
Age at diagnosis
(mean ± SD), years
66 ± 9 66 ± 9 66 ± 8 63 ± 11 0.029 67 ± 9 63 ± 8 < 0.001
BMI at diagnosis
(mean ± SD), kg/m2
26.5 ± 4.0 26.0 ± 4.0 26.5 ± 3.9 29.2 ± 4.1 < 0.001 26.5 ± 3.9 26.6 ± 4.3 0.66
BMI at diagnosis, kg/m2 < 0.001 0.64
< 18.5 10 (1%) 3 (1%) 6 (1%) 0 (0%) 6 (1%) 4 (1%)
18.5–25 447 (39%) 130 (47%) 301 (38%) 13 (19%) 331 (39%) 107 (38%)
25–30 497 (43%) 110 (39%) 352 (45%) 27 (39%) 362 (43%) 122 (43%)
30–35 161 (14%) 27 (10%) 107 (14%) 23 (33%) 120 (14%) 37 (13%)
> 35 37 (3%) 9 (3%) 22 (3%) 6 (9%) 25 (3%) 12 (4%)
Education level 0.061 0.37
Low 505 (44%) 133 (48%) 330 (42%) 36 (52%) 383 (45%) 115 (41%)
Medium 277 (24%) 58 (21%) 198 (25%) 20 (29%) 195 (23%) 72 (26%)
High 365 (32%) 87 (31%) 260 (33%) 13 (19%) 262 (31%) 95 (34%)
Smoking at diagnosis 0.005 0.27
Yes 133 (11%) 47 (17%) 73 (9%) 11 (16%) 102 (12%) 25 (9%)
Former 682 (59%) 166 (60%) 468 (59%) 40 (58%) 498 (59%) 168 (59%)
Never 334 (29%) 67 (24%) 247 (32%) 18 (26%) 240 (28%) 89 (32%)
Tumour stage 0.26 < 0.001
I 299 (26%) 60 (22%) 218 (28%) 19 (28%) 297 (35%) –
II 350 (30%) 96 (34%) 229 (29%) 19 (28%) 311 (37%) 27 (10%)
III 503 (44%) 123 (44%) 341 (43%) 31 (45%) 236 (28%) 255 (90%)
Tumour location 0.038 < 0.001
Colon 778 (68%) 206 (74%) 517 (66%) 45 (65%) 499 (59%) 259 (92%)
Rectum 374 (32%) 73 (26%) 271 (34%) 24 (35%) 345 (41%) 23 (8%)
Adjuvant chemotherapy 0.18 –
Yes 282 (24%) 80 (29%) 184 (23%) 16 (23%) – 282
(100%)
No 844 (73%) 192 (69%) 587 (74%) 52 (75%) 844
(100%)
–
Adjuvant chemotherapy
regimen
0.94 –
Capecitabine + oxaliplatin 214 (19%) 61 (22%) 140 (18%) 12 (17%) – 214 (76%)
Capecitabine 37 (3%) 12 (4%) 22 (3%) 2 (3%) – 37 (13%)
Other 7 (1%) 2 (1%) 5 (1%) 0 (0%) – 7 (2%)
Neo-adjuvant treatment 0.34 < 0.001
Yes 270 (23%) 57 (20%) 189 (24%) 19 (28%) 250 (30%) 15 (5%)
No 882 (77%) 222 (79%) 599 (76%) 50 (72%) 594 (70%) 267 (95%)
Stoma 0.061 < 0.001
Yes 340 (30%) 67 (24%) 245 (31%) 22 (32%) 309 (37%) 25 (9%)
No 783 (68%) 207 (74%) 521 (66%) 46 (67%) 508 (60%) 255 (90%)
Surgery 0.054 0.67
Laparoscopic 725 (63%) 162 (58%) 512 (65%) 38 (55%) 538 (64%) 177 (62%)
Conversion 73 (6%) 18 (6%) 46 (6%) 9 (13%) 51 (6%) 21 (7%)
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Compared to pre-diagnosis weight, mean weight change
was −0.8 (95% CI −1.1, −0.4) kg over the 4-year period
(Table 2). Over this total period, weight change was < 5%
for the majority of people (66%), while 14% of all patients
experienced pre-to-post diagnosis weight gain of ≥ 5% and
20% experienced weight loss of ≥ 5%. When only the 2 years
post-diagnosis were taken into account, mean weight change
in the 2 years after diagnosis was + 1.2 (95%CI 0.9, 1.5) kg.
The estimated 4-year weight trajectory in the entire cohort
is presented in Fig. 1A. The full model showed a clear positive
quadratic relationship of weight changes in the entire cohort
(p < 0.001), but no linear effect was present (+ 0.04 kg annual
weight gain, p = 0.68). In other words, weight decreased be-
fore diagnosis while weight increased after diagnosis. Overall,
weight 2 years after diagnosis was similar to weight 2 years
before diagnosis.
To explore if post-diagnosis weight trajectories differed by
pre-diagnosis weight change, we stratified the weight trajec-
tory analyses by pre-diagnosis weight change. A mean gain in
body weight after diagnosis was most prominent in the group
that had lost weight before diagnosis (Fig. 1B; Table 2). In this
group, 42% gained weight after diagnosis and this proportion
was much larger than that seen for the pre-diagnosis weight
stable and weight gain groups (14% and 19%, respectively;
Table 2). In absolute numbers, post-diagnosis weight gain was
on average + 3.5 (95% CI 2.7, 4.3) kg in the group that had
lost weight pre-diagnosis. However, taking the 2 years before
diagnosis into account, mean weight change was −4.8 (95%
CI −5.7, −3.9) kg in this group. On average, clinically relevant
weight change after diagnosis was absent when pre-diagnosis
weight was stable or when pre-diagnosis weight gain ≥ 5%
was present.
Weight trajectories were similar for those treated with and
without adjuvant chemotherapy (Fig. 1C; Table 2). In both
groups, overall weight 2 years after diagnosis was similar to
overall weight 2 years before diagnosis. Sensitivity analyses
excluding patients with other adjuvant chemotherapy regi-
mens than capecitabine combined with oxaliplatin or exclud-
ing patients with rectal tumours did not change the results
(data not shown). Weight trajectories were similar for those
with a BMI of 18.5–25 kg/m2 and a BMI ≥ 25 kg/m2 at diag-
nosis (data not shown).
Discussion
We examined pre-to-post diagnosis weight trajectories among
patients with non-metastatic CRC. Overall, hardly any pre-to-
post diagnosis weight change was observed among CRC pa-
tients, because post-diagnosis weight gain was mainly ob-
served in patients who lost weight before diagnosis. This
was observed independent of treatment with adjuvant
chemotherapy.
This was the first study that examined pre-to-post diagnosis
weight changes in CRC patients, therefore we can only com-
pare our results on post-diagnosis weight changes with previ-
ous studies. All previous studies on post-diagnosis weight
change in CRC patients with non-metastatic disease showed
that weight gain was more common than weight loss [1–3, 10,
11, 17], which is in line with our study. We found that 21% of
patients with non-metastatic CRC experienced ≥ 5% weight
gain in the first 2 years after diagnosis, which is slightly lower
than the 28% reported in previous studies [1, 2]. Among pa-
tients treated with adjuvant chemotherapy, 27% of patients
experienced ≥ 5% weight gain in our study. Although the pro-
portion of patients treated with chemotherapy who experi-
enced weight gain in the current study was lower compared
with other studies (36–65%) [3, 10, 11], the mean post-
diagnosis weight gain of + 2.1 kg in patients treated with che-
motherapy was similar to the mean weight gain of + 2.0 kg
reported in a previous study based on body weights retrieved
from medical records [11]. Weight gain was seen both during
Table 1 (continued)
Weight change in the 2 years before diagnosis Adjuvant chemotherapy
Overall2 Loss
(≥ 5%)
Stable (−5% to 5%) Gain
(≥ 5%)
p value weight
change group
No Yes p value chemo
therapy
Open 303 (26%) 84 (30%) 198 (25%) 19 (28%) 213 (25%) 76 (27%)
Complications
after surgery
< 0.001 < 0.001
Yes 323 (28%) 96 (35%) 195 (25%) 26 (37%) 257 (30%) 55 (20%)
No 787 (68%) 170 (61%) 569 (72%) 40 (58%) 553 (66%) 220 (78%)
Comorbidity 0.023 0.018
Yes 773 (67%) 182 (65%) 524 (67%) 56 (81%) 581 (69%) 173 (61%)
No 370 (32%) 97 (35%) 256 (32%) 12 (17%) 256 (30%) 107 (38%)
1 Some counts do not add to totals because of missing data
2 Includes 16 participants with missing pre-diagnosis weight and 26 with missing chemotherapy status
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and after adjuvant chemotherapy [11], although in this study
we were not able to make this distinction. While previous
studies focussed on post-diagnosis weight changes, the cur-
rent study also included usual weight pre-diagnosis into the
analysis of weight changes. Our analyses revealed that post-
diagnosis weight gain was most prominent in patients who
lost ≥ 5% weight before diagnosis and therefore mean pre-
to-post diagnosis weight gain was absent in the overall
population.
The current study was the first that compared weight
changes between CRC patients treated with and without adju-
vant chemotherapy. By including weight data at multiple time
points during the course of the disease, both before and after
diagnosis, we showed that weight trajectories were similar for
those treated with and without chemotherapy. In both groups,
weight 2 years post-diagnosis diagnosis did on average not
surpass usual pre-diagnosis weight. However, in both groups,
about 15% experienced pre-to-post diagnosis weight gain of
≥ 5%. It was unexpected that weight trajectories over the
course of CRC were independent of adjuvant chemotherapy
treatment. Previous studies showed that post-diagnosis weight
gain was more common in studies among patients treated with
adjuvant therapy than in studies that included patients irre-
spective of adjuvant chemotherapy (36–65% versus 28%, re-
spectively) [1–3, 10, 11]. Our results imply that weight gain is
not a common side-effect of adjuvant chemotherapy in CRC
patients with non-metastatic disease.
A limitation of this study is that body weight was self-
reported at each time point, perhaps leading to measurement
error with regard to weight change. Cross-sectional data show
that self-reported weight values are typically slightly lower
than directly measured values [18], although bias may differ
by weight status and gender [18, 19]. However, good-to-
excellent agreement was reported for self-reported and direct-
ly measured values of body weight in studies with similar
demographic characteristics to this study [20, 21].
Participants are also likely to have internal consistency in their
reporting, such that the degree of underreporting will be sim-
ilar each time [19]. Therefore, changes in weight may be less
prone to such bias than individual weight measurements. In
our study, weight 2 years prior to diagnosis was recalled while
post-diagnosis weights were collected prospectively, which
may decrease internal consistency. However, good-to-
excellent agreement was also reported for pre-diagnosis
weight recalled shortly after diagnosis and directly measured
values of pre-diagnosis body weight [22]. We assume that
weight 2 years before CRC diagnosis reflects usual pre-
diagnosis weight, since the median time from onset of symp-
toms (such as weight loss) until the start of treatment is usually
4 to 5 months [23, 24]. Another limitation is that we did not
have information on changes in body composition. Even
when pre-to-post diagnosis weight gain is not present, post-
diagnosis weight gain may still lead to an increase in fat mass
with a loss in muscle mass. Future research should be done to
determine how post-diagnosis weight gain affects body
composition.
This study has several strengths. First, the COLON study
provided an opportunity to explore weight trajectories over the
Table 2 Two-year post-diagnosis and 4-year pre-to-post diagnosis weight changes by pre-diagnosis weight change groups and by adjuvant
chemotherapy1
Weight change during 2 years before diagnosis Adjuvant chemotherapy
Overall Loss (≥ 5%) Stable (−5% to 5%) Gain (≥ 5%) No Yes
N (%) 922 (100%) 221 (24%) 644 (70%) 57 (6%) 687 (75%) 215 (23%)
Pre-diagnosis weight change
(mean (95% CI)), kg
−1.9 (−2.3, −1.6) −8.3 (−9.1, −7,5) −0.5 (−0.6, −0.3) +6.2 (5.5, 6.8) −1.9 (−2.2, −1.5) −2.2 (−2.8, −1.5)
Pre-to-post diagnosis weight change (4 years)
Absolute weight change
(mean (95% CI)), kg
−0.8 (−1.1, −0.4) −4.8 (−5.7, −3.9) +0.0 (−0.3, 0.4) +6.1 (4.5, 7.6) −0.9 (−1.4, −0.5) −0.1 (−0.8, 0.6)
Weight loss (%) 20 48 11 4 21 16
Weight stable (%) 66 47 76 30 65 69
Weight gain (%) 14 5 12 67 14 15
Post-diagnosis weight change
(2 years)
Absolute weight change
(mean (95% CI)), kg
+1.2 (0.9, 1.5) +3.5 (2.7, 4.3) +0.5 (0.2, 0.8) −0.1 (−1.7, 1.5) +0.9 (0.5, 1.3) +2.1 (1.5, 2.7)
Weight loss (%) 9 5 9 26 10 6
Weight stable (%) 70 54 77 55 71 67
Weight gain (%) 21 42 14 19 19 27
1 230 participants with pre-diagnosis weight and/or 2-year post-diagnosis weight information missing omitted from table (n = 16 and n = 217,
respectively)
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course of the disease in a large group of CRC patients, since
we prospectively collected weight several times after
diagnosis and also had pre-diagnosis weight available. We
used mixed models to examine weight trajectories over
4 years. An advantage of mixed models is that participants
with incomplete weight data were still included in the analy-
ses. Second, we had detailed treatment information available
so we were able to compare weight trajectories between those
treated with and without adjuvant chemotherapy. Third, we
were able to adjust for many covariates that could potentially
affect weight change. Although other factors, such as physical
activity and physical functioning, not included in the multi-
variate analyses could also affect weight change. However,
both the adjusted weight trajectories (Fig. 1) and the crude
weight changes (Table 2) showed similar results. Lastly, the
study population was representative of the total population of
Dutch stage I–III CRC survivors with respect to stage of dis-
ease and location of the tumour (colon or rectum), but the
proportion of females and the mean age were slightly lower
as compared to the total population of CRC survivors [25, 26].
Although not perfectly comparable, we believe our findings
are generalizable to the total Dutch population of stage I–III
CRC survivors, but they cannot be generalised to stage IV
CRC survivors.
In clinical practice, not only weight loss, but also weight
gain should receive attention as is stated in the Dutch
Dieticians Oncology Group guidelines for bowel cancer
therapy [5]. Based on our results, weight changes should
be monitored over the course of the disease in all patients,
taking pre-diagnosis weight change into account. A previ-
ous study suggested that pre-to-post diagnosis weight
change, weight loss as well as weight gain, may be associ-
ated with a higher mortality risk among CRC patients with
non-metastatic disease [1]. In contrast, post-diagnosis
weight gain did not seem to be associated with mortality
risk [1, 2, 10]. Our results, together with these other studies
[1, 2, 10], emphasise the importance of taking pre-
diagnosis weight into account when examining weight
changes in CRC patients. Our study showed that 14% of
all patients experienced pre-to-post diagnosis weight gain
and pre-to-post diagnosis weight gain was equally preva-
lent among patients treated with and without adjuvant che-
motherapy. Therefore, weight gain prevention should not
only be targeted at patients receiving adjuvant chemother-
apy, but at all CRC patients with non-metastatic disease.
In conclusion, pre-to-post diagnosis weight change was
largely absent among CRC patients with non-metastatic dis-
ease, because post-diagnosis weight gain was mainly ob-
served in patients who lost weight before diagnosis. This
was observed independent of treatment with adjuvant chemo-
therapy. Future studies are needed to confirm our findings and
to assess how weight change relates to survival and the devel-
opment of co-morbidities to provide a solid basis for future
recommendations directed towards managing weight during
the course of CRC.
Total group (n=1137)
By pre-diagnosis weight change group (n=1125)
By adjuvant chemotherapy treatment status (n=1112)
a
b
c
Fig. 1 Weight trajectories from 2 years before diagnosis to 2 years after
diagnosis in colorectal cancer patients (weight trajectories were based on
predicted values from mixed models for a population with laparoscopic
surgery and of average age, height, education, sex, smoking status,
complications, stoma, type of surgery, and comorbidities). A. Total
group (n = 1137) B. By pre-diagnosis weight change group (n = 1125)
C. By adjuvant chemotherapy treatment status (n = 1112)
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